Cargando…

An immune risk score predicts progression-free survival of melanoma patients in South China receiving anti-PD-1 inhibitor therapy—a retrospective cohort study examining 66 circulating immune cell subsets

INTRODUCTION: Immune checkpoint blockade inhibitor (ICI) therapy offers significant survival benefits for malignant melanoma. However, some patients were observed to be in disease progression after the first few treatment cycles. As such, it is urgent to find convenient and accessible indicators tha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chi, Peidong, Jiang, Hang, Li, Dandan, Li, Jingjing, Wen, Xizhi, Ding, Qiyue, Chen, Linbin, Zhang, Xiaoshi, Huang, Junqi, Ding, Ya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768215/ https://www.ncbi.nlm.nih.gov/pubmed/36569825 http://dx.doi.org/10.3389/fimmu.2022.1012673

Ejemplares similares

Next-generation sequencing in advanced Chinese melanoma reveals therapeutic targets and prognostic biomarkers for immunotherapy
por: Huang, Fuxue, et al.
Publicado: (2022)

Time-varying pattern of recurrence risk for localized melanoma in China
por: Wen, Xizhi, et al.
Publicado: (2020)

Nomogram for predicting prognosis of patients with metastatic melanoma after immunotherapy: A Chinese population–based analysis
por: Zhao, Jingjing, et al.
Publicado: (2022)

Effect of age and cancer on peripheral immune cell subsets and their PD-1 and PD-L1 expression
por: Grenga, Italia, et al.
Publicado: (2015)

Changes of peripheral T cell subsets in melanoma patients with immune-related adverse events
por: Müller, Benjamin, et al.
Publicado: (2023)

Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma
por: Zhao, Jing-Jing, et al.
Publicado: (2020)

Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy
por: Carbone, Maria Luigia, et al.
Publicado: (2023)

Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
por: Shiuan, Eileen, et al.
Publicado: (2017)

Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients
por: Machiraju, Devayani, et al.
Publicado: (2021)

PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments
por: Valentini, Anna Maria, et al.
Publicado: (2018)

The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies
por: Wu, Chiao-En, et al.
Publicado: (2020)

HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
por: Huang, Fu-xue, et al.
Publicado: (2022)

Novel Immune Subsets and Related Cytokines: Emerging Players in the Progression of Liver Fibrosis
por: Wan, Minjie, et al.
Publicado: (2021)

Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study
por: Qin, Yong, et al.
Publicado: (2017)

Imbalance of T Lymphocyte Subsets in Adult Immune Thrombocytopenia
por: Lin, Xiuxiu, et al.
Publicado: (2021)

Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma
por: Pennington, Thomas E, et al.
Publicado: (2022)

Cryoablation combined with transarterial infusion of pembrolizumab (CATAP) for liver metastases of melanoma: an ambispective, proof-of-concept cohort study
por: Shen, Lujun, et al.
Publicado: (2020)

A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure
por: Xiao, Wei, et al.
Publicado: (2018)

Immune cell subset differentiation and tissue inflammation
por: Fang, Pu, et al.
Publicado: (2018)

Whole‐exome sequencing in clear cell sarcoma of soft tissue uncovers novel prognostic categorization and drug targets
por: Li, Jingjing, et al.
Publicado: (2021)

Landscape of Infiltrated Immune Cell Characterization in Uveal Melanoma to Improve Immune Checkpoint Blockade Therapy
por: Lv, Xiaohui, et al.
Publicado: (2022)

Changes and Clinical Significance of Detailed Peripheral Lymphocyte Subsets in Evaluating the Immunity for Cancer Patients
por: Qiu, Jinrong, et al.
Publicado: (2020)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
por: Wang, Yuanyuan, et al.
Publicado: (2021)

Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma
por: Woo, Taylor E., et al.
Publicado: (2023)

Efficacy of immune-checkpoint inhibitors in PD-L1 selected or unselected patients vs. control group in patients with advanced or metastatic urothelial carcinoma
por: Guo, Lifang, et al.
Publicado: (2021)

Immunological analyses reveal an immune subtype of uveal melanoma with a poor prognosis
por: Pan, Hui, et al.
Publicado: (2020)

The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint
por: Wang, Qingshui, et al.
Publicado: (2017)

Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma
por: Frias, Alex, et al.
Publicado: (2023)

An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers
por: Bottai, Giulia, et al.
Publicado: (2016)

Spitz Melanoma is a Distinct Subset of Spitzoid Melanoma
por: Raghavan, Shyam, et al.
Publicado: (2020)

Diosgenin promotes antitumor immunity and PD-1 antibody efficacy against melanoma by regulating intestinal microbiota
por: Dong, Mengxue, et al.
Publicado: (2018)

A PD-L1-Based Cancer Vaccine Elicits Antitumor Immunity in a Mouse Melanoma Model
por: Lin, Zhibing, et al.
Publicado: (2019)

Cellular immunity augmentation in mainstream oncologic therapy
por: Chen, Daohong, et al.
Publicado: (2017)

ICOS(+) Tregs: A Functional Subset of Tregs in Immune Diseases
por: Li, Dan-Yang, et al.
Publicado: (2020)

Comprehensive Immune Profiling Unveils a Subset of Leiomyosarcoma with “Hot” Tumor Immune Microenvironment
por: Feng, Xiaolan, et al.
Publicado: (2023)

Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma
por: Placke, Jan-Malte, et al.
Publicado: (2021)

Identification of lung adenocarcinoma subtypes and predictive signature for prognosis, immune features, and immunotherapy based on immune checkpoint genes
por: Hua, Linbin, et al.
Publicado: (2023)

PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates
por: Pico de Coaña, Yago, et al.
Publicado: (2020)

Tailored Immune Responses: Novel Effector Helper T Cell Subsets in Protective Immunity
por: Kara, Ervin E., et al.
Publicado: (2014)

Specifically differentiated T cell subset promotes tumor immunity over fatal immunity
por: Ramadan, Abdulraouf, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_eqojqeecttr8erdb3hvqjj5j46